drugset / Trial / NCT01472562
Lenalidomide Plus Rituxan for Untreated Mantle Cell Lymphoma
Phase 2
Completed
38 enrolled
Weill Medical College of Cornell University
Celgene Corporation · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a phase II, multicenter study to determine the efficacy and safety of first-line lenalidomide plus rituximab therapy in patients with mantle cell lymphoma who have received no prior systemic therapy.
Timeline
- Start
- 2011-07-29
- Primary completion
- 2014-04
- Completion
- 2023-07-30
Publications
- Yamshon S, Chen GZ, Gribbin C, Christos P, Shah B, Schuster SJ, Smith SM, Svoboda J, Furman RR, Leonard JP, Martin P, Ruan J. Nine-year follow-up of lenalidomide plus rituximab as initial treatment for mantle cell lymphoma. Blood Adv. 2023 Nov 14;7(21):6579-6588. doi: 10.1182/bloodadvances.2023010606.
- Ruan J, Martin P, Christos P, Cerchietti L, Tam W, Shah B, Schuster SJ, Rodriguez A, Hyman D, Calvo-Vidal MN, Smith SM, Svoboda J, Furman RR, Coleman M, Leonard JP. Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphoma. Blood. 2018 Nov 8;132(19):2016-2025. doi: 10.1182/blood-2018-07-859769. Epub 2018 Sep 4.
- Ruan J, Martin P, Shah B, Schuster SJ, Smith SM, Furman RR, Christos P, Rodriguez A, Svoboda J, Lewis J, Katz O, Coleman M, Leonard JP. Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma. N Engl J Med. 2015 Nov 5;373(19):1835-44. doi: 10.1056/NEJMoa1505237.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lenalidomide | Other / unclassified | 15 mg | — |
| Subject | Rituximab | Monoclonal antibody | 375 mg/m2 | — |